Glenmark Pharma Closes Trading Window for Q2 FY27

Glenmark Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with the Prohibition of Insider Trading Regulations, 2015, and the company's internal code of conduct. The trading window will be shut for designated persons, including directors, key managerial personnel, identified employees, and their immediate relatives, as well as connected persons. The closure commences from October 01, 2026, and will remain in effect until the declaration of the unaudited financial results (standalone and consolidated) for the second quarter ended September 30, 2026, plus forty-eight hours thereafter. The specific date for the board meeting to approve these results will be communicated separately.